Have a feature idea you'd love to see implemented?
Let us know!
MNOV Medicinova Inc
Price (delayed)
$1.81
Market cap
$88.77M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.16
Enterprise value
$44.63M
MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a primary commercial focus on the U.S.
Highlights
MNOV's EPS is up by 36% year-on-year and by 6% since the previous quarter
MNOV's net income is up by 34% YoY and by 2.9% from the previous quarter
The equity has declined by 12% year-on-year and by 4.1% since the previous quarter
The quick ratio has contracted by 5% from the previous quarter and by 5% YoY
Key stats
What are the main financial stats of MNOV
Market
Valuations
Earnings
Shares outstanding
49.05M
Market cap
$88.77M
Enterprise value
$44.63M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.55
Price to sales (P/S)
88.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
44.63
Revenue
$1M
EBIT
-$8.16M
EBITDA
-$7.96M
Free cash flow
-$8.55M
Per share
Balance sheet
Liquidity
EPS
-$0.16
Free cash flow per share
-$0.17
Book value per share
$1.17
Revenue per share
$0.02
TBVPS
$1.04
Total assets
$60.4M
Total liabilities
$3M
Debt
$190,047
Equity
$57.41M
Working capital
$43.01M
Debt to equity
0
Current ratio
18.24
Quick ratio
17.78
Net debt/EBITDA
5.55
Margins
Efficiency
Dividend
EBITDA margin
-795.8%
Gross margin
100%
Net margin
-816.5%
Operating margin
-936.6%
Return on assets
-12.7%
Return on equity
-13.4%
Return on invested capital
-216.7%
Return on capital employed
-14.1%
Return on sales
-816.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MNOV stock price
How has the Medicinova stock price performed over time
Intraday
1.69%
1 week
0%
1 month
-4.74%
1 year
-10.4%
YTD
20.67%
QTD
-13.81%
Financial performance
How have Medicinova's revenue and profit performed over time
Revenue
$1M
Gross profit
$1M
Operating income
-$9.37M
Net income
-$8.16M
Gross margin
100%
Net margin
-816.5%
MNOV's net income is up by 34% YoY and by 2.9% from the previous quarter
The operating income is up by 32% year-on-year and by 2.7% since the previous quarter
MNOV's operating margin is up by 2.7% QoQ
The net margin has grown by 2.9% from the previous quarter
Growth
What is Medicinova's growth rate over time
Valuation
What is Medicinova stock price valuation
P/E
N/A
P/B
1.55
P/S
88.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
44.63
MNOV's EPS is up by 36% year-on-year and by 6% since the previous quarter
The P/B is 26% lower than the 5-year quarterly average of 2.1 but 19% higher than the last 4 quarters average of 1.3
The equity has declined by 12% year-on-year and by 4.1% since the previous quarter
The stock's P/S is 12% more than its last 4 quarters average of 79.5
Efficiency
How efficient is Medicinova business performance
MNOV's ROIC has shrunk by 171% YoY but it is up by 6% QoQ
Medicinova's return on equity has increased by 26% YoY
The ROA rose by 25% YoY
MNOV's return on sales is up by 2.9% since the previous quarter
Dividends
What is MNOV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MNOV.
Financial health
How did Medicinova financials performed over time
MNOV's total liabilities is down by 15% YoY and by 2.1% QoQ
MNOV's total assets is down by 12% year-on-year and by 4% since the previous quarter
The debt is 100% less than the equity
The debt has contracted by 13% from the previous quarter and by 6% YoY
The equity has declined by 12% year-on-year and by 4.1% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.